If validated in subsequent trials across diverse populations, such treatments could help reduce the burden of cardiometabolic disease and improve patients' overall quality of life worldwide
Treatment of pituitary and other tumours with cabergoline: new mechanisms and potential broader applications
Injectable weight loss drugs mimic the positive effects of GLP-1
This protocol mirrors the evidence from clinical trials showing improved weight loss outcomes and better tolerability when patients follow structured dose escalation rather than jumping to higher doses immediately
Products that lean too hard on gimmicky GLP-1 branding are unlikely to build durable trust
GLP-1RAS AND DIABETIC RETINOPATHY The phenomenon of worsening diabetic retinopathy (DR), often termed rebound retinopathy, is a well-established, paradoxical retinal finding linked to improved blood glucose levels, typically observed 3 months to 3 years after intense glucose lowering